| Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma N Rastgoo, J Wu, A Liu, M Pourabdollah, EG Atenafu, D Reece, W Chen, ... Haematologica 105 (12), 2813, 2020 | 43 | 2020 |
| Pim kinases in multiple myeloma J Wu, E Chu, Y Kang Cancers 13 (17), 4304, 2021 | 20 | 2021 |
| MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma L Zhang, N Rastgoo, J Wu, M Zhang, M Pourabdollah, E Zacksenhaus, ... Cancer Letters 480, 29-38, 2020 | 14 | 2020 |
| SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma J Wu, M Zhang, O Faruq, E Zacksenhaus, W Chen, A Liu, H Chang Biomarker Research 9 (1), 48, 2021 | 12 | 2021 |
| SLAMF7 as a promising immunotherapeutic target in multiple myeloma treatments E Chu, J Wu, SS Kang, Y Kang Current Oncology 30 (9), 7891-7903, 2023 | 7 | 2023 |
| Efficacy of nucleoside analogues on hepatitis B virus-related liver failure: A network meta-analysis J Wu, F Yin, X Zhou Acta Pharmaceutica 68 (1), 19-30, 2018 | 6 | 2018 |
| PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo Y Sha, J Wu, B Paul, Y Zhao, P Mathews, Z Li, J Norris, E Wang, ... Cancer letters 545, 215832, 2022 | 5 | 2022 |
| Anaplastic multiple myeloma: case series and literature review J Wu, E Chu, CC Chase, T Choi, C Gasparetto, K Young, Y Kang Asploro journal of biomedical and clinical case reports 5 (1), 1, 2022 | 5 | 2022 |
| Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma J Wu, E Chu, B Paul, Y Kang Cancers 14 (21), 5272, 2022 | 3 | 2022 |
| Downregulation of MDM2 Leads to Anti-Proliferative Effects through Activation of P53-Associated Pathway Mediated By Both Dual Inhibitor MX69 and Mir-548c-3p in Multiple Myeloma F Faruq, D Zhao, J Wu, JNG William, M Zhang, H Chang Blood 134, 4419, 2019 | 3 | 2019 |
| RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect J Wu, X Wang, M Zhang, P Mathews, Y Kang Cells 12 (15), 1993, 2023 | 2 | 2023 |
| Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma J Wu, S Fan, D Feinberg, X Wang, S Jabbar, Y Kang Current Oncology 30 (3), 3047-3063, 2023 | 2 | 2023 |
| Ascendancy of unfolded protein response over glioblastoma: estimating progression, prognosis and survival R Gundamaraju, J Wu, JNG William, W Lu, NK Jha, S Ramasamy, PV Rao Biotechnology and Genetic Engineering Reviews 39 (1), 143-165, 2023 | 2 | 2023 |
| Overexpression of Mir-21-5p induces apoptosis and cell cycle arrest by down-regulating SKP2 and overcomes bortezomib resistance in multiple myeloma JNG William, J Wu, Z Chen, O Faruq, H Chang Blood 134, 1823, 2019 | 1 | 2019 |
| Inhibition of Sphingosine Kinase 2 Enhances Immunotherapy in Mouse Model of Multiple Myeloma Y Kang, X Wang, J Wu, S Jabbar, CT Jiang, X Shen, B Ogretmen Blood 142, 876, 2023 | | 2023 |
| Development of Thioredoxin Monothiol Derivatives for Mitigating Radiation Induced Hematopoietic Injury Y Kang, J Wu, X Wang, P Mathews, S Jabbar, GW Schaaf, J Olson, J Ross, ... Blood 142, 3639, 2023 | | 2023 |
| Role of PPAR Receptor and Ligands in the Pathogenesis and Therapy of Hematologic Malignancies J Wu, M Zhang, A Faircloth Hemato 3 (3), 422-433, 2022 | | 2022 |
Eldad ZacksenhausProfessor of Medicine, University of TorontoVerified email at utoronto.ca
